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Abstract
Purpose Contrary to the approved indication for
pegfilgrastim prophylaxis, some patients receive it on the
same day as the last administration of chemotherapy in clinical
practice, which could adversely impact risk of febrile neutro-
penia (FN). An evaluation of the timing of pegfilgrastim pro-
phylaxis and FN risk was undertaken.
Methods A retrospective cohort design and data from two US
private health care claims repositories were employed. Study
population comprised adults who received intermediate/high-
risk chemotherapy regimens for solid tumors or non-
Hodgkin’s lymphoma (NHL) and received pegfilgrastim pro-
phylaxis in ≥1 cycle; all cycles with pegfilgrastimwere pooled
for analyses. Odds ratios (OR) for FN during the cycle were
estimated for patients who received pegfilgrastim on the same
day (day 1) as the last administration of chemotherapy versus
days 2–4 from chemotherapy completion.
Results The study population included 45,592 patients who re-
ceived pegfilgrastim in 179,152 cycles (n=37,095 in cycle 1); in
12 % of cycles, patients received pegfilgrastim on the same day
as chemotherapy. Odds of FNwere higher for patients receiving
pegfilgrastim prophylaxis on the same day as chemo-
therapy versus days 2–4 from chemotherapy in cycle 1
(OR=1.6, 95 % CI=1.3–1.9, p<0.001) and all cycles
(OR=1.5, 95 % CI=1.3–1.6, p<0.001).
Conclusions In this large-scale evaluation of adults who re-
ceived intermediate/high-risk regimens for solid tumors or
NHL in US clinical practice, FN incidence was found to be
significantly higher among those who received pegfilgrastim
prophylaxis on the same day as chemotherapy completion
versus days 2–4 from chemotherapy completion,
underscoring the importance of adhering to the indicated ad-
ministration schedule.
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Introduction
Neutropenia is a common side effect of myelosuppressive
chemotherapy that increases the risk of infection. When neu-
tropenic patients develop fever (i.e., febrile neutropenia (FN)),
the high likelihood of infection and serious consequences of-
ten necessitate hospitalization for urgent evaluation, ongoing
monitoring, and administration of intravenous (IV) antibiotics
[1, 2]. FN, as well as severe or prolonged neutropenia, can
lead to chemotherapy dose-delays, dose-reductions, and/or
discontinuation, interfering with the delivery of optimal
cancer treatment and possibly adversely affecting patient
outcomes [1, 3–7].
For adult patients receiving chemotherapy for solid tumors
or non-myeloid malignancies, clinical practice guidelines rec-
ommend prophylaxis with a colony-stimulating factor (CSF)
when FN risk is high (>20 %) based on either chemotherapy
regimen risk alone or a combination of regimen risk and pa-
tient risk factors [1, 8]. Among the CSFs that are commercial-
ly available in the USA, pegfilgrastim is the agent most widely
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used in clinical practice as, unlike the other agents that are
administered daily, it requires only a single dose in each che-
motherapy cycle [9–12]. Because pegfilgrastim rapidly in-
duces the proliferation of myeloid progenitor cells—which
may be especially sensitive to myelotoxic agents and could
adversely impact the risk of FN—prescribing information
specifies that pegfilgrastim should not be administered be-
tween 14 days before and 24 h after administration of myelo-
suppressive chemotherapy. The National Comprehensive
Cancer Network (NCCN) guidelines on myeloid growth fac-
tor use state that Bthe majority of trials administered
pegfilgrastim the day after chemotherapy^ (based on category
1 evidence: high-level evidence, there is uniform NCCN con-
sensus that the intervent ion is appropria te) and
Badministration of pegfilgrastim up to 3–4 days after chemo-
therapy is also reasonable based on trials with filgrastim^ [8,
12–18]. Similarly, the recently promulgated American Society
of Clinical Oncology (ASCO) guidelines indicate that
pegfilgrastim should be administered on days 2–4 from che-
motherapy completion, if possible [1].
Accumulating—albeit limited—evidence from clinical
practice suggests that many patients receive pegfilgrastim on
the same day as the last administration of chemotherapy, rath-
er than during days 2–4 from chemotherapy completion,
which often requires an extra clinic visit [19–22]. Several
studies have evaluated the efficacy/effectiveness of
pegfilgrastim prophylaxis administered on the same day as
chemotherapy versus the day(s) after chemotherapy, but these
studies have been small, have sometimes been inconclusive,
and have—taken collectively—produced mixed results [20,
23–31]. Moreover, the NCCN guidelines state that Blimited
data suggest that same-day administration of pegfilgrastim
may be considered in certain circumstances,^ and that such
use of pegfilgrastim is done for Blogistical reasons and to
minimize burdens on long-distance patients^ [8]. In addition,
the ASCO guidelines indicate that because some patients may
not be able to return on days 2–4 from chemotherapy comple-
tion due to—for example—distance or mobility, it is better to
administer same-day pegfilgrastim than no pegfilgrastim [1].
Accordingly, a retrospective evaluation was undertaken to
provide real-world evidence on the use and potential implica-
tions of the timing of pegfilgrastim prophylaxis among adults
who received intermediate/high-risk chemotherapy regimens
for solid tumors or non-Hodgkin’s lymphoma (NHL) in US
clinical practice.
Methods
Study design and data source
This study employed a retrospective cohort design and data
from two large health care claims repositories spanning the
period from January 1, 2003, through December 31, 2011.
Patient-level claims data from the two repositories were
pooled for analyses. The two study repositories―Truven
Health Analytics MarketScan® Commercial Claims and En-
counters and Medicare Supplemental and Coordination of
Benefits Databases (MarketScan Database) and IMS
LifeLink™ PharMetrics Plus Health Plan Claims Database
(LifeLink Database)―comprise medical (i.e., facility and pro-
fessional service) and outpatient pharmacy claims from a large
number of participating private US health plans.
The study databases were de-identified prior to their release
to study investigators, and thus, their use for health services
research is fully compliant with the HIPAA Privacy Rule and
federal guidance on Public Welfare and the Protection
of Human Subjects [32]. A detailed description of study
design and study methods may be found in the online
supplement (Online Resource A).
Source and study populations
The source population comprised all patients aged ≥18 years
who, between July 1, 2003, and June 30, 2011, received ≥1
course of myelosuppressive chemotherapy for a single prima-
ry solid tumor or NHL. Patients who did not have medical and
drug benefits for ≥6 months prior to their qualifying chemo-
therapy course or who did not meet other inclusion criteria (as
described in the online supplement) were excluded from the
source population. For each patient in the source population,
the first unique observed course of chemotherapy, and each
cycle within the first course, was identified. From the source
population, all patients who received intermediate/high-risk
chemotherapy regimens and pegfilgrastim prophylaxis in
≥1 cycle of chemotherapy were selected for inclusion in the
study population. To ensure adequate sample size for cancer/
regimen-specific analyses, the study population was fur-
ther limited on an a priori basis to patients who received
chemotherapy regimens that are commonly used in US
clinical practice [11, 33, 34].
Pegfilgrastim prophylaxis was ascertained based on corre-
sponding Healthcare Common Procedure Coding System
(HCPCS) level II codes (C9119, S0135, J2505) on medical
claimswith service dates on or up to 3 days after the last day of
chemotherapy administration in a given cycle. Patient-cycles
with pegfilgrastim prophylaxis were categorized into sub-
groups based on whether pegfilgrastim was administered on
the same day as the last administration of chemotherapy (same
day [day 1] as chemotherapy) versus during days 2–4 from
completion of chemotherapy (days 2–4 from chemotherapy)
and were pooled for analyses. (Because all chemotherapy reg-
imens considered in this study are fully administered on the
first day of the cycle, Bsame day as chemotherapy^ refers to
cycle day 1.) To minimize confounding, patient-cycles were
excluded if there was evidence of prophylaxis with other CSF
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or antibiotic agents or if there was evidence of FN prior to
administration of pegfilgrastim during the cycle.
FN episodes
FN episodes were ascertained during the period beginning on
day 5 from chemotherapy completion through the last day of
that cycle and were identified using a Bbroad^ definition as
follows [35]: FN episodes requiring inpatient care were iden-
tified based on hospital admissions with a principal or second-
ary diagnosis of neutropenia (ICD-9-CM 288.0), or fever
(780.6), or infection. FN episodes requiring outpatient care
only were identified based on ambulatory encounters (e.g.,
those in a physician’s office, emergency department, or home)
with a diagnosis of neutropenia, or fever, or infection and—on
the same date—a HCPCS level I (i.e., CPT) code for IV ad-
ministration of antimicrobial therapy. Such encounters that
preceded or followed an FN-related hospitalization during
the same cycle of chemotherapy were not considered as a
separate outpatient episode (i.e., they were classified as part
of the episode of FN requiring inpatient care). An alternative
(narrow) definition for FN comprising inpatient encounters
with a principal or secondary diagnosis of neutropenia, and
outpatient encounters with a diagnosis of neutropenia and ev-
idence of IV antimicrobial therapy, was also evaluated [35].
Patient, cancer, and treatment characteristics
Characteristics included age; sex; presence of selected chronic
comorbidities (cardiovascular disease, diabetes, liver disease,
lung disease, renal disease, osteoarthritis, rheumatoid disease,
thyroid disorder); body weight/nutritional status (obesity, un-
derweight, malnutrition); proxies for health status (hospice/
skilled nursing facility (SNF) care) and physical function
(use of hospital bed, supplemental oxygen, walking aid,
wheelchair); use of immunosuppressive therapy; history of
blood disorders (anemia, neutropenia, other), infection, recent
surgery, hospitalization (all-cause), chemotherapy, and radia-
tion therapy; total health care expenditures during the baseline
period; and calendar year of chemotherapy initiation. All char-
acteristics (except for recent surgery) were assessed during the
12-month pre-chemotherapy period; recent surgery was
assessed during the 90-day pre-chemotherapy period.
Statistical analyses
Odds ratios for FN—unadjusted and adjusted for characteris-
tics of patients, their cancer, and their chemotherapy regi-
men—among patients who received pegfilgrastim prophylax-
is on the same day as chemotherapy versus days 2–4 from
chemotherapy were estimated using generalized estimating
equations (GEE) with a binomial distribution, logistic link
function, and exchangeable correlation structure. The GEE
method accounts for correlation among repeated measures
for the same subject (in this instance, among cycles), while
controlling for both variables that are invariant as well as those
that may vary across observations. Adjusted analyses were
conducted using backward selection of the aforementioned
patient, cancer, and treatment characteristics.
Analyses were conducted considering all study subjects,
the first cycle, and all FN episodes (i.e., irrespective of care
setting), as well as considering all cycles, inpatient FN epi-
sodes only, and the narrow definition for FN, respectively.
Analyses also were conducted within subgroups of the study
population defined on the basis of cancer type and chemother-
apy regimen.
All statistical tests were two-sided and were performed at a
significance level of α=0.05; adjustments for multiple com-
parisons were not employed. Assuming that pegfilgrastim
would be administered on the same day as chemotherapy in
13 % of cycles, and that FN risk would be higher in these
cycles by 50 % (4.5 vs. 3 %), the minimum total sample
size—corresponding to 80 % power, with two-sided α=
0.05—was calculated to be approximately 11,000 patients
[24, 26, 33].
Results
A total of 491,990 adult patients underwent a course of mye-
losuppressive chemotherapy for a single primary solid tumor
or NHL from July 2003 through June 2011 and met all other
patient-level criteria for inclusion in the source population
(Online Resource B). Among these patients, 45,592 received
one of the selected intermediate/high-risk chemotherapy reg-
imens, received pegfilgrastim prophylaxis in ≥1 cycle, and
met all cycle-level criteria for inclusion in the study popula-
tion. Study subjects received pegfilgrastim prophylaxis in a
total of 179,152 cycles (n=37,095 in cycle 1); in 12 % of
cycles, patients received pegfilgrastim on the same day as
chemotherapy administration (and thus in a manner inconsis-
tent with the indicated schedule).
Among study subjects who received pegfilgrastim prophy-
laxis in cycle 1, 78 % had non-metastatic breast cancer (54 %
of these patients received doxorubicin+cyclophosphamide
with or without subsequent docetaxel or paclitaxel [AC-T/
AC, dose-dense]), 14 % had NHL (cyclophosphamide+doxo-
rubicin+vincristine+prednisone with or without rituximab
[R-CHOP/CHOP]), 5 % had non-metastatic lung cancer
(carboplatin+paclitaxel [CAR+PAC]), and 3 % had non-
metastatic ovarian cancer (CAR+PAC). Baseline characteris-
tics of patients receiving pegfilgrastim prophylaxis on the
same day as chemotherapy versus days 2–4 from chemother-
apy were generally comparable; although some characteristics
were statistically different between subgroups, such variation
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in values was not clinically meaningful (e.g., mean age, 54.5
vs. 55.5 years, p<0.001) (Table 1).
On an overall basis, the incidence proportion for FN (all
episodes) during first cycles among patients receiving
pegfilgrastim prophylaxis on the same day as chemotherapy
was 3.9 %, versus 2.8 % among those receiving prophylaxis
on days 2–4 from chemotherapy; the corresponding adjusted
odds ratio was 1.6 (95 % CI=1.3–1.9, p value <0.001)
(Fig. 1). The incidence proportion for FN (all episodes) during
all cycles with pegfilgrastim prophylaxis was 2.5 % (same day
as chemotherapy) versus 1.9 % (days 2–4 from chemothera-
py), and the corresponding adjusted odds ratio was 1.5 (95 %
CI=1.3–1.6, p value <0.001). Adjusted odds ratios when con-
sidering all cycles and only inpatient FN episodes (OR=1.5,
95 % CI=1.3–1.6, p value <0.001)—which accounted for
86 % of all episodes—and the narrow definition for FN
(OR=2.0, 95 % CI=1.8–2.3, p value <0.001) were com-
parable. Tables describing the selection of source/study
populations, baseline characteristics of patients within
cancer/regimen-specific subgroups, and odds ratios for
FN within cancer/regimen-specific subgroups are set forth
in the online supplement (Online Resource B).
Discussion
Prescribing information specifies that pegfilgrastim
should not be administered between 14 days before
and 24 h after administration of myelosuppressive che-
motherapy, and the majority of data from clinical trials
provide evidence on the efficacy of pegfilgrastim and
thus support its use according to this schedule [9,
14–16]. The results of our study suggest, however, that
an important minority (12 %) of cancer patients receiv-
ing pegfilgrastim prophylaxis during intermediate/high-
risk chemotherapy regimens for solid tumors and NHL
in US clinical practice receives pegfilgrastim in a man-
ner inconsistent with prescribing information (i.e., on
the same day as chemotherapy administration).
More notably, the results of this study also suggest that the
odds of FN are substantially higher (by 1.5–2.0 times) among
patients who receive pegfilgrastim on the same day as chemo-
therapy versus those who receive pegfilgrastim on days 2–4
from chemotherapy. These results were found to be robust
when considering the first cycle only, all cycles, only inpatient
FN episodes, and a narrow definition for FN. While the
precise reasons for the timing of pegfilgrastim administra-
tion in our study are unknown, the use of prophylaxis on
the same day as chemotherapy should be carefully con-
sidered by providers as the results of this study suggest
that such use may lead to additional FN events, most of
which require hospitalization and are associated with se-
vere consequences [2, 4, 19, 36, 37].
While recognizing the inherent limitations of retrospective
evaluations using health care claims databases, we note that
the findings described herein are based on analyses of over 37,
000 patients (and nearly 180,000 chemotherapy cycles) with a
broad spectrum of cancer/regimen combinations, which is
substantially larger than the collective populations in all of
the aforementioned published studies. In the four studies that
support use of pegfilgrastim prophylaxis according to the in-
dicated schedule—including two retrospective evaluations
and two randomized trials—sample sizes ranged from 75 to
214, while in the three studies that provide evidence in support
of same-day prophylaxis—including two retrospective evalu-
ations and one randomized trial—sample sizes ranged from 46
to 230 [20, 24–27]. Evidence from randomized trials was re-
ported by Burris and colleagues, who conducted four individ-
ual phase II randomized, double-blind studies of patients with
breast cancer (n=90), NHL (n=75), non-small cell lung can-
cer (NSCLC) (n=88), and ovarian cancer (n=19), respective-
ly, across 74 clinical sites [24]. In the breast cancer and NHL
trials, the incidence of severe neutropenia in cycle 1 was found
to be higher, and the duration of severe neutropenia longer,
among patients who received pegfilgrastim on the same day as
chemotherapy versus those who received it on the day after
chemotherapy. In the NSCLC trial, however, the incidence
and duration of severe neutropenia in cycle 1 were found to
be comparable between the same-day and next-day prophy-
laxis groups. Comparisons of patients with ovarian cancer
were limited due to premature discontinuation of the trial.
We mention a few important limitations and possibilities
for bias in the current study. In clinical practice, patients who
received pegfilgrastim prophylaxis on the same day as che-
motherapy may be systematically different than those who
received prophylaxis on days 2–4 from chemotherapy, and
to the extent such differences are unobserved, study results
may be biased. Because there is no ICD-9-CM diagnosis code
for FN, codes for neutropenia, fever, and infection were
employed to identify inpatient and outpatient encounters that
are assumed to be related to FN. Since patients are typically
not given chemotherapy when they are neutropenic or have
active infection, the appearance of codes for neutropenia, fe-
ver, or infection within a defined exposure period after receiv-
ing chemotherapy increases the likelihood that such outcomes
are related to receipt of chemotherapy. While the sensitivity of
the broad definition for FN used in this study is likely higher
than that of the narrow definition using only the ICD-9-CM
code for neutropenia, the specificity and positive predictive
value are likely lower, chiefly due to the inclusion of infec-
tions occurring in the absence of fever and neutropenia [35].
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Table 1 Characteristics of
patients receiving pegfilgrastism
prophylaxis on same day as
chemotherapy completion versus
days 2–4 from chemotherapy
completion










Age (years),mean (SD) 54.5 (11.0) 55.5 (11.4) <0.001
Male, % 11.0 10.7 0.612
Chronic comorbidities, %
Cardiovascular disease 8.3 8.9 0.194
Diabetes 11.0 11.6 0.237
Liver disease 1.8 2.4 0.025
Lung disease 3.8 4.6 0.023
Renal disease 1.3 1.6 0.086
Osteoarthritis 5.8 6.4 0.108
Rheumatoid disease 1.0 1.1 0.446
Thyroid disorder 9.8 9.6 0.542
Body weight and nutritional status, %
Obese 3.0 3.0 0.954
Underweight 0.0 0.0 0.503
Malnutrition 0.3 1.4 0.419
Proxies for health status, %
Hospice care 0.2 0.3 0.235
SNF 1.1 1.0 0.633
Hospice or SNF 1.2 1.3 0.892
Proxies for physical function, %
Use of hospital bed 0.2 0.2 0.696
Use of supplemental oxygen 2.2 1.6 0.012
Use of walking aid 1.3 1.5 0.549
Use of wheel chair 0.3 0.5 0.183
Any of the above 3.7 3.3 0.179
Use of immunosuppresive drugs, % 7.4 7.9 0.194
History of other conditions/events, %
Anemia 11.2 13.5 <0.001
Neutropenia 3.9 4.1 0.530
Other blood disorders 4.8 6.1 0.001
Infection 33.2 33.7 0.501
Recent surgery (prior 90 days) 62.9 64.4 0.049
History of hospitalization for any reason 37.8 37.6 0.782
History of chemotherapy 0.1 0.0 0.007
History of radiation therapy 4.0 4.1 0.784
Pre-chemotherapy expenditures ($), mean (SD) 30,818 (23,448) 29,338 (23,292) <0.001
Chemotherapy
Year of chemotherapy, %
2003–2005 19.2 16.2 <0.001
2006–2008 49.8 40.2
2009–2011 31.0 43.5
*Same day as chemotx: receipt on last day of chemotherapy administration; days 2–4 from chemotx: receipt 1–
3 days following the last day of chemotherapy administration
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The likelihood of FN occurring after cycle day 14 is low, and
some infection-related encounters may occur after
chemotherapy-induced neutropenia has resolved [38]. While
the precise direction and magnitude of this bias is unknown,
there is no reason to believe that the bias should dispropor-
tionately impact patients receiving prophylaxis on the same
day as chemotherapy versus days 2–4 from chemotherapy.
Because the accuracy of algorithms/variables captur-
ing the presence of acute and chronic conditions is
undoubtedly less than perfect, and because histories
are left-truncated, some patients may be misclassified
in terms of their comorbidity profile and/or pre-
chemotherapy health care experience. Similarly, the ac-
curacy of our algorithms for identifying the primary
cancer type and presence of metastatic disease is un-
known. Finally, because the study population principal-
ly comprised cancer patients aged less than 65 years
with coverage from private US health plans, the study
population may not reflect US patients treated in clin-
ical practice across the USA. Consequently, study re-
sults may not be generalizable to those with public
health insurance, the uninsured, and older patients.
In summary, in this retrospective evaluation of cancer
patients receiving pegfilgrastim during intermediate/
high-risk regimens for solid tumors and NHL in US
clinical practice, one in every eight patients received
prophylaxis on the same day as chemotherapy
administration. FN risk among these subsets was sub-
stantially higher than it was among those who received
it on days 2–4 from chemotherapy. The results of this
study underscore the importance of adhering to the in-
dicated administration schedule for pegfilgrastim.
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